anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in "real life" conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised.
The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
The invention belongs to the field of biological medicine, and relates to a preparation method and application of a glucose-sensitive insulin delivery system. The glucose-sensitive insulin delivery system consists of an inner core and an outer layer, wherein insulin and mesoporous silica are used as the inner core, and glucose-sensitive materials capable of responding to different blood glucose concentrations and anionic polymers capable of promoting absorption of the system across a mucus layer are used as the outer layer. The glucose sensitive material is selected from: 4-formyl phenylboronic acid grafted chitosan or 4-carboxyl-3-fluorobenzeneboronic acid grafted chitosan; mesoporous silica: insulin: the mass ratio of the 4-formyl benzene boric acid grafted chitosan or the 4-carboxyl-3-fluorobenzene boric acid grafted chitosan is 1-2: 0.5-2: 0.5-2. The anionic polymer promoting absorption of the system across the mucus layer is selected from: phosphoserine. The glucose-sensitive insulin oral administration system prepared by the invention has the particle size of 90-900nm, and the drug-loading rate can reach more than 25%, which is higher than that of the common organic nanoparticle administration system. The system has obvious blood sugar reducing effect.
The primary objective of this study is to assess the effects of rasagiline on cognitive deficits in non-demented patients with PD. The secondary objective is to assess affective changes in this patient population. This will be a randomized, double-blind, placebo controlled study in 1-3 centers. Patients will be recruited from the Movement Disorders Outpatients Clinic, Department of Neurology, Istanbul Faculty of Medicine, Dokuz Eylul University and Marmara University. Eligible patients will be randomly assigned to rasagiline 1 mg or placebo. Patients will be treated with the study medication over 3 months. Cognitive and behavioral assessments will be performed at baseline, at 4 weeks and at the end of the study, at 12 weeks. A total of 40 PD patients with cognitive deficits, but without dementia will be recruited. No sample size calculation will be performed, a sample of convenience will be used.
Bottle gourd (Lagenaria siceraria (Mol.) Strandl.) is an economically important vegetable crop and one of the earliest domesticated crops. However, the population history and genomic diversification of bottle gourd have not been extensively studied. We generated a comprehensive bottle gourd genome variation map from genome sequences of 197 world-wide representative accessions, which enables a genome-wide association study for identifying genomic loci associated with resistance to zucchini yellow mosaic virus, and constructed a bottle gourd pangenome that harbors 1534 protein-coding genes absent in the reference genome. Demographic analyses uncover that domesticated bottle gourd originated in Southern Africa c. 12 000 yr ago, and subsequently radiated to the New World via the Atlantic drift and to Eurasia through the efforts of early farmers in the initial Holocene. The identified highly differentiated genomic regions among different bottle gourd populations harbor many genes contributing to their local adaptations such as those related to disease resistance and stress tolerance. Presence/absence variation analysis of genes in the pangenome reveals numerous genes including those involved in abiotic/biotic stress responses that have been under selection during the world-wide expansion of bottle gourds. The bottle gourd variation map and pangenome provide valuable resources for future functional studies and genomics-assisted breeding.
Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
The invention relates to preparation and application of a recombinant protein for treating inflammatory bowel disease, wherein the recombinant protein gene is derived from intestinal bacteria AKKERMANSIA MUCINIPHILA and is named Amuc _1434. The research of the invention shows that the recombinant protein has better treatment effect on inflammatory bowel disease. The Amuc _1434 gene is successfully cloned to an escherichia coli expression vector, and then the recombinant protein Amuc _1434 is obtained after induced expression purification. Experiments prove that the recombinant protein Amuc-1434 provided by the invention can obviously relieve the symptoms of UC mice, slow down colon shortening, reduce the level of inflammatory cytokines, reduce organism oxidative stress and reduce intestinal tissue lesion degree. In addition, the recombinant protein Amuc-1434 also has the protective effect on the kidney, and the effect is better than that of the common colitis treatment medicament mesalamine on the market. The invention provides a scientific basis for the application of the recombinant protein Amuc-1434 in the treatment of inflammatory bowel disease, and lays a foundation for further developing a novel recombinant protein medicament for the treatment of inflammatory bowel disease.
Locoregional recurrence of non-small-cell lung cancer (NSCLC) after complete resection lacks standard treatment. Durvalumab after chemoradiotherapy (CRT) or CRT alone is often selected in daily clinical practice for patients with locoregional recurrence; however, the therapeutic efficacy of these treatments remains unclear, and we aimed to assess this. This retrospective observational study used data from patients with NSCLC diagnosed with locoregional recurrence after complete resection who subsequently underwent concurrent CRT followed by durvalumab (CRT-D group) or CRT alone (CRT group). We employed propensity score analysis with inverse probability treatment weighting (IPTW) to adjust for various confounders and evaluate efficacy in the CRT-D group. After IPTW adjustment, the CRT-D group contained 119 patients (64.7% male; 69.7% adenocarcinoma), and the CRT group contained 111 patients (60.5% male; 73.4% adenocarcinoma). Their mean ages were 66 and 65 years, respectively. The IPTW-adjusted median progression-free survival was 25.4 and 11.5 months for the CRT-D and CRT groups, respectively (hazard ratio, 0.44; 95% confidence interval, 0.30-0.64); the median overall survival was not reached in either group favoring CRT-D (hazard ratio, 0.49; 95% confidence interval, 0.24-0.99). Grade 3 or 4 adverse events were observed in 48.8% of patients during CRT, 10.7% after initiating durvalumab maintenance therapy in the CRT-D group, and 57.3% in the CRT group. Overall, the sequential approach of CRT followed by durvalumab is a promising treatment strategy for locoregional recurrence of NSCLC after complete resection.
The Post Covid-19 Condition (commonly known as Long Covid) has been defined by the World Health Organisation as occurring in individuals with a history of probable or confirmed SARS CoV 2 infection, usually within 3 months from the onset of acute Covid-19 infection with symptoms that last for at least two months which cannot be explained by an alternative diagnosis. Long Covid is associated with over two hundred recognised symptoms and affects tens of millions of people worldwide. Widely reported reductions in quality of life(QoL) and functional status are caused by extremely sensitive and cyclical symptom profiles that are augmented following exposure to physical, emotional, orthostatic, and cognitive stimuli. This manifestation prevents millions of people from engaging in routine activities of daily living (ADLs) and has important health and well-being, social and economic impacts. Post-exertional symptom exacerbation (PESE) (also known as post-exertional malaise) is an exacerbation in the severity of fatigue and other symptoms following physical, emotional, orthostatic and cognitive tasks. Typically, this will occur 24-72 h after "over-exertion" and can persist for several days and even weeks. It is a hallmark symptom of Long Covid with a reported prevalence of 86%. The debilitating nature of PESE prevents patients from engaging in physical activity which impacts functional status and QoL. In this review, the authors present an update to the literature relating to PESE in Long Covid and make the case for evidence-based guidelines that support the design and implementation of safe rehabilitation approaches for people with Long Covid. This review also considers the role of objective monitoring to quantify a patient's response to external stimuli which can be used to support the safe management of Long Covid and inform decisions relating to engagement with any stimuli that could prompt an exacerbation of symptoms.
Lumbar disc herniation is usually caused by the accumulation of long-term mechanical loads and sudden overload damage. Therefore, this study aims to illustrate how fatigue failure in lumbar spine segments is influenced by both cyclic loading magnitude and pre-existing damage. Eighty-six sheep intervertebral disc samples were divided into four groups to test the fatigue responses in healthy and damaged intervertebral discs. Both before and after fatigue loading, the specimens were performed on loading-unloading tests to analyze the viscoelasticity changes, while the specimens were performed on MRI examination to analyze the geometric and morphological changes. The Stress-Failure curve (SN curve) was examined, while the number of cycles to failure of damaged specimens was much smaller than that of healthy specimens at the same stress level during cyclic loading, and the relationship was approximately linear on a logarithmic scale. In addition, the healthy specimens will not accumulate fatigue failure if the compression force remains below 50% of the ultimate compressive tolerance (UTC). Before and after fatigue loading, the loading-unloading curves do not coincide and show obvious strain-rate-dependent viscoelastic characteristics, while the elastic modulus of the damaged specimen is significantly smaller. For magnetic resonance imaging, morphological changes included the changes of nucleus pulposus (NP) shape and area, while fatigue has a more significant effect on ruptured and herniated disc specimens. The dissipated energy of the intervertebral discs under cyclic loading was then calculated based on viscoelastic constitutive equations, which show that the load and preexisting damage both have significant effects on the dissipation rate.
After obtaining verbal and written consent from the participants, they are required to answer the questions on the Diagnosis Form, Acute Coronary Syndrome Response Index, and Multiple Quality of Life Scale. Then, preliminary measurements will be made and a 6-minute corridor walking test will be applied. While the control group will be followed up routinely, the training booklet prepared for the intervention group will be explained orally. Participants will then be informed that they will be called monthly. They will be told that they can reach these monthly calls and consult the nurse when they need it. After this stage, interviews with patients will begin. The standard way of communication with the participants by the researchers is by telephone, and a total of 6 interviews will be provided, the first of which is in the 1st month after the application of the tests. In each call, all the information in the training booklet will be repeated, additional information will be given in line with the needs and demands of the person, their questions will be answered and the interview will be ended. Although it varies according to the individual interviewed, it is predicted that these telephone interviews will last for 30 minutes on average. Apart from these standard calls, individuals in need will be able to reach the researcher face-to-face during phone calls, text messages, instant messaging methods or hospital visits, and in this way, the counseling process will continue actively for 6 months. After six months, the final tests will be done.
The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
The present invention is concerned with a method for determining the presence of a malignant condition at a locus of interest. An exfoliative cell specimen obtained from the locus is contacted with an antibody specific for an antigenic site that is usually only found in the specimen when a malignant condition is present. The contact is made under conditions for detectable binding of the antibody to such antigenic site. After contact, the presence of binding of the antibody to the antigenic site is observed. The binding of the antibody is related to the presence of a malignant condition at the locus. The invention finds utility, for example, in the detection of cervical carcinoma.
BACKGROUND: Neuroinflammation contributes to both epileptogenesis and the associated neurodegeneration, so regulation of inflammatory signaling is a potential strategy for suppressing epilepsy development and pathological progression. Exosomes are enriched in microRNAs (miRNAs), considered as vital communication tools between cells, which have been proven as potential therapeutic method for neurological disease. Here, we investigated the role of miR129-5p-loaded mesenchymal stem cell (MSC)-derived exosomes in status epilepticus (SE) mice model.
METHODS: Mice were divided into four groups: untreated control (CON group), kainic acid (KA)-induced SE groups (KA group), control exosome injection (KA + Exo-con group), miR129-5p-loaded exosome injection (KA + Exo-miR129-5p group). Hippocampal expression levels of miR129-5p, HMGB1, and TLR4 were compared among groups. Nissl and Fluoro-jade B staining were conducted to evaluate neuronal damage. In addition, immunofluorescence staining for IBA-1 and GFAP was performed to assess glial cell activation, and inflammatory factor content was determined by ELISA. Hippocampal neurogenesis was assessed by BrdU staining.
RESULTS: The expression of HMGB1 was increased after KA-induced SE and peaking at 48 h, while hippocampal miR129-5p expression decreased in SE mice. Exo-miR129-5p injection reversed KA-induced upregulation of hippocampal HMGB1 and TLR4, alleviated neuronal damage in the hippocampal CA3, reduced IBA-1 + and GFAP + staining intensity, suppressed SE-associated increases in inflammatory factors, and decreased BrdU + cell number in dentate gyrus.
CONCLUSIONS: Exosomes loaded with miR129-5p can protect neurons against SE-mediated degeneration by inhibiting the pro-inflammatory HMGB1/TLR4 signaling axis.
Malaria in humans is caused by infection with  Plasmodium  species parasites including  P. vivax . The biology and immunobilogy of  P. vivax  is distinct from that of  P. falciparum . Provided are unique synthetic polypeptides and DNA molecules which encode them. Each of these molecules correspond to regions of the circumsporozoite protein of  P. vivax . Each molecule comprises sequences corresponding to several repeats of the central region of the Pv 210 variant fused to sequences corresponding to several repeats of the central region of the Pv 247 variant. Each molecule additionally comprises sequences corresponding to either the amino terminus, the carboxy terminus, or both the amino and carboxy termini of the PvCSP. Also provided are vaccines comprising these unique sequences and methods of using these vaccines and sequences to prevent and treat Pv malaria.
ECa 233 is a standardized extract of Centella asiatica with known anti-inflammatory properties and an acceptable safety profile. Hence, it would be relevant to evaluate the anti-inflammatory and pain reducing effects of ECa 233 on subjects with acute TMD, as well as jaw functional movements. A randomized, double-blind, placebo- and active-controlled clinical trial was performed on 18 to 50-year-old participants with acute TMD. These were randomly assigned to four treatment groups for 14 days: placebo, ibuprofen, ECa 233 250mg and 500 mg. At baseline, subjects reported 5 to 8 of pain intensity on a numerical rating scale (NRS). No medications were self-reported 24 h before and during the trial and no systemic conditions were diagnosed. Degenerative joint disease was screened before treatment. Pain intensity levels, mandibular range of motion including pain-free, unassisted and assisted mouth opening at baseline and days7 and 14 post-treatment. Masticatory muscle and jaw joint tenderness were evaluated upon palpation.
OBJECTIVES: To explore the clinical effect of electroacupuncture (EA) on promoting gastrointestinal function recovery in patients undergoing laparoscopic gastrectomy.
METHODS: One hundred and twenty patients undergoing laparoscopic gastrectomy were randomly divided into an EA group (40 cases, 1 case was eliminated), a placebo EA (PEA) group (40 cases, 1 case dropped out) and a conventional treatment group (40 cases, 1 case dropped out). The patients in the conventional treatment group received perioperative routine treatment. On the basis of routine treatment, patients in the EA group and the PEA group were given electroacupuncture or placebo electroacupuncture stimulation at 24,48 and 72 h after anesthesia recovery. Bilateral Neiguan (PC 6), Zusanli (ST 36) and Shangjuxu (ST 37) were selected, and the electrodes of SDV-Z electroacupuncture instrument were connected to Zusanli (ST 36) and Shangjuxu (ST 37) on the same side respectively. Continuous wave was selected, the frequency was 5 Hz, and the needles were retained for 30 min each time. The postoperative gastrointestinal-2 ( GI-2 ) time, the incidence of grade A/B delayed gastric emptying were compared among the three groups, and the safety of acupuncture was evaluated.
RESULTS: The GI-2 time of the EA group was significantly shorter than that of the PEA group and the conventional treatment group (P<0.05). The incidence of grade A and grade B of delayed gastric emptying in the EA group was lower than that in the PEA group and the conventional treatment group (P<0.05). No acupuncture-related adverse reactions occurred.
CONCLUSIONS: EA can promote the recovery of gastrointestinal function in patients undergoing laparoscopic gastrectomy, and the treatment plan is safe, which is worthy of promotion and application into the enhanced recovery surgery program.
Systems and methods are provided for setting up and sending healthcare alerts (e.g. immunization reminders) to patients/caregivers through the use of communications devices. In an embodiment, information about a patient's/caregiver's wireless device (e.g. cell phones) is collected and reported to an immunization registry. The registry is linked to a system that uses the wireless device information to generate automatic wireless immunization reminders, recalls and educational messages that are sent to the patient/caregiver. In a preferred embodiment, opt-in information is reported to the system to ensure that the patient/caregiver has consented to the automatic wireless immunization reminders. The system may also check the eligibility of patients to receive reminders, provide incentives for patients to receive reminders, provide follow up information (e.g. performed, not performed, responses to message/s) to a healthcare provide for a particular patient or a group of patients, and/or provide billing services for payment of the reminders.
The invention relates to a preparation method of oat beta-glucan. Oat bran is adopted as a raw material, and the oat beta-glucan is obtained by low-temperature extraction, high-temperature extraction, treatment by pectase and amylase, primary alcohol precipitation, vacuum drying, secondary alcohol precipitation and vacuum drying. The purity of a prepared product can achieve 67.1%, the yield is 4.2%, the protein content is 1.7%, the main advantage of the preparation method is that the extraction and the purification processes are simple, and the characteristics of the preparation method are mainly represented as the unique low-temperature extraction step and the pectase treatment process in the technology. The low-temperature extraction can remove most of starch in the raw material so as to enable the follow-up process to be performed better. By using the pectase, the traditional protein removal step is abandoned in the technology, and impurities, such as proteins and the like, are ingeniously removed by centrifugation while removing pectine. In the technology, the secondary alcohol precipitation is finally adopted for further purification, thereby obtaining the product with good dissolubility and stable characters, and having important significant for large-scale production, development and utilization.
Provided is an alkyloxirane derivative represented by formula (1). M H  and M L  calculated from the chromatogram obtained from the gel permeation chromatography measurement of the alkyloxirane derivative satisfy the relationship represented by formula (2). Z–[O–(AO)n–H]x … (1) (Z represents residues that remain after all hydroxyl groups are removed from a compound containing 1 to 22 carbon atoms and 1 to 6 hydroxyl groups. x represents a number of 1 to 6. AO represents an oxyalkylene group containing 3 carbon atoms. n represents a number of at least 25.) 0.35 ≤ M L /M H  ≤ 0.75 … (2) (L represents the length of a vertical line extending from a maximum point K on the chromatogram, which represents the maximum magnitude of the refractive index, to a base line B. Points O and Q represent the two points on the chromatogram at which the magnitude of the refractive index becomes L/2, where the elution time is shorter at point O and the elution time is longer at point Q. M H  is the distance between point O and intersection point P, and M L  is the distance between point Q and intersection point P, when P is the point at which a straight line G connecting point O and point Q intersects with the vertical line extending from the maximum point K to the base line.)